首页> 美国卫生研究院文献>Annals of The Royal College of Surgeons of England >Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report
【2h】

Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report

机译:接受FOLFIRI-Aflibercept治疗结直肠癌的患者坏死性筋膜炎:病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier’s gangrene.
机译:抗血管生成已成为治疗几种类型的肿瘤(例如卵巢癌,乳腺癌,肺癌和结直肠癌)的重要组成部分。贝伐单抗已报告坏死性筋膜炎,但大肠癌患者中无阿柏西普,雷莫昔单抗或瑞戈非尼的报道。坏死性筋膜炎是一种罕见的并发症,影响了每5000名贝伐单抗使用者中的一名。我们报道了一例患有IV期直肠乙状结肠癌的64岁男性,该患者正在接受亚叶酸,氟尿嘧啶和伊立替康(FOLFIRI)和阿柏西普的治疗,这些患者发展出了Fournier的坏疽。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号